Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease

Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer’s disease

Abstract Background We aimed to investigate the clinical correlates of principal components (PCs) of tau positron emission tomography (PET) and their predictability for longitudinal changes in tau accumulation in Alzheimer’s disease (AD). Methods We enrolled 272 participants who underwent two PET sc...

Full description

Bibliographic Details
Main Authors:	Hanna Cho, Min Seok Baek, Hye Sun Lee, Jae Hoon Lee, Young Hoon Ryu, Chul Hyoung Lyoo
Format:	Article
Language:	English
Published:	BMC 2020-09-01
Series:	Alzheimer’s Research & Therapy
Subjects:	Alzheimer’s disease Positron emission tomography Tau 18F-flortaucipir
Online Access:	http://link.springer.com/article/10.1186/s13195-020-00685-4

Similar Items

Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms
by: Chul Hyoung Lyoo, et al.
Published: (2018-01-01)

Topographic staging of tau positron emission tomography images
by: Adam J. Schwarz, et al.
Published: (2018-01-01)

Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease
by: Min Seok Baek, et al.
Published: (2020-10-01)

Escalation of Tau Accumulation after a Traumatic Brain Injury: Findings from Positron Emission Tomography
by: Abdalla Z. Mohamed, et al.
Published: (2022-07-01)

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study
by: Michael J. Pontecorvo, et al.
Published: (2020-06-01)

Dynamic network model reveals distinct tau spreading patterns in early- and late-onset Alzheimer disease
by: Wha Jin Lee, et al.
Published: (2022-09-01)

Detection of individual brain tau deposition in Alzheimer's disease based on latent feature-enhanced generative adversarial network
by: Jiehui Jiang, et al.
Published: (2024-05-01)

Tau pathology in cognitively normal older adults
by: Jacob Ziontz, et al.
Published: (2019-12-01)

Tauvid™: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer’s Disease
by: Caitlin V. M. L. Jie, et al.
Published: (2021-01-01)

An updated radiosynthesis of [18F]AV1451 for tau PET imaging
by: Andrew V. Mossine, et al.
Published: (2017-06-01)

Head injury is associated with tau deposition on PET in MCI and AD patients
by: Shannon L. Risacher, et al.
Published: (2021-01-01)

Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [18F]-APN-1607 Study
by: Huiwei Zhang, et al.
Published: (2021-06-01)

In vivo network models identify sex differences in the spread of tau pathology across the brain
by: Sepideh Shokouhi, et al.
Published: (2020-01-01)

Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults
by: Matthew R. Scott, et al.
Published: (2020-10-01)

Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data
by: Christina B. Young, et al.
Published: (2021-11-01)

Direct comparison between 18F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy
by: Ryota Satoh, et al.
Published: (2024-02-01)

Large inter- and intra-case variability of first generation tau PET ligand binding in neurodegenerative dementias
by: Melissa C. Wren, et al.
Published: (2018-05-01)

Tau Filaments and the Development of Positron Emission Tomography Tracers
by: Michel Goedert, et al.
Published: (2018-02-01)

Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies
by: Cinzia Maschio, et al.
Published: (2022-04-01)

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET
by: Shannon L. Risacher, et al.
Published: (2018-10-01)

18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
by: Niklas Mattsson, et al.
Published: (2017-09-01)

Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimagingResearch in context
by: Stephanie Doering, et al.
Published: (2024-05-01)

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia
by: Dawn C. Matthews, et al.
Published: (2021-01-01)

Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET studyResearch in context
by: Natasha Krishnadas, et al.
Published: (2023-02-01)

Plasma tau complements CSF tau and P‐tau in the diagnosis of Alzheimer's disease
by: Silvia Fossati, et al.
Published: (2019-12-01)

Compensating for choroid plexus based off-target signal in the hippocampus using 18F-flortaucipir PET
by: Daria Pawlik, et al.
Published: (2020-11-01)

Cross‐sectional and longitudinal atrophy is preferentially associated with tau rather than amyloid β positron emission tomography pathology
by: Brian A. Gordon, et al.
Published: (2018-01-01)

Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer’s disease continuum
by: Hillary Protas, et al.
Published: (2023-03-01)

[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
by: Marta Marquié, et al.
Published: (2019-10-01)

In vivo imaging of tau deposition in Alzheimer’s disease using both [18F]-THK5317 and [18F]-S16: A pilot human study
by: Liping Fu, et al.
Published: (2022-08-01)

Toxic tau: structural origins of tau aggregation in Alzheimer's disease
by: Abdullah Al Mamun, et al.
Published: (2020-01-01)

In vivo coupling of tau pathology and cortical thinning in Alzheimer's disease
by: Elijah Mak, et al.
Published: (2018-01-01)

The Sensitivity of Tau Tracers for the Discrimination of Alzheimer’s Disease Patients and Healthy Controls by PET
by: Zohreh Mohammadi, et al.
Published: (2023-02-01)

Findings of 18F‐PI‐2620 tau PET imaging in patients with Alzheimer’s disease and healthy controls in relation to the plasma P‐tau181 levels in a Japanese sample
by: Shogyoku Bun, et al.
Published: (2022-12-01)

Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET
by: Seun Jeon, et al.
Published: (2019-08-01)

Untangling tau imaging
by: Victor L. Villemagne, et al.
Published: (2016-01-01)

Dissociation of Tau Deposits and Brain Atrophy in Early Alzheimer’s Disease: A Combined Positron Emission Tomography/Magnetic Resonance Imaging Study
by: Yoko Shigemoto, et al.
Published: (2018-07-01)

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective
by: Maria Ricci, et al.
Published: (2021-11-01)

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease
by: Juan Lantero-Rodriguez, et al.
Published: (2024-02-01)

Prediction of rapid amyloid and phosphorylated‐Tau accumulation in cognitively healthy individuals
by: Ivan Koychev, et al.
Published: (2020-01-01)